Summary

The global Live-type Poultry Vaccine market is projected to grow from US$ 1931 million in 2025 to US$ 2578 million by 2032, at a CAGR of 4.6% (2026-2032), driven by critical product segments and diverse end‑use applications.

Live-type Poultry Vaccines are veterinary biological products containing immunogenic live attenuated viruses, attenuated bacteria, live parasites, or replicating recombinant viral vectors that retain limited replication capability in the host and are used to prevent infectious diseases and establish vaccination programs in chickens and other poultry. By disease type, the product is classified into Newcastle Disease Vaccines, Infectious Bronchitis Vaccines, Infectious Bursal Disease Vaccines, Marek's Disease Vaccines, and Others; by Antigen Combination, into Monovalent Vaccines and Multivalent/Combination Vaccines; and by Function, into Preventive Vaccines, Prime Vaccines, and Booster Vaccines. Major formulations include freeze-dried live vaccines, frozen cell-associated vaccines, and recombinant live-vector vaccines, administered through spray, drinking water, eye/nose drops, subcutaneous injection, or in-ovo vaccination. Core parameters include dose per bird, EID50, TCID50, PFU or CFU potency, attenuation and genetic stability, onset and duration of immunity, maternal-antibody interference, and storage conditions. A representative live Newcastle vaccine can contain ≥10^6 EID50 per dose and require 2–8°C storage, while HVT-vector products are primarily administered in ovo or at one day of age.

Key Findings
The average industry gross margin of the product in 2025 is approximately 45%–65%.

Newcastle Disease Vaccines represent the largest segment, with Clone 30, B1, and LaSota being representative live strains and Clone 30 providing a typical potency of ≥10^6 EID50 per dose.

Broiler Farming represents the largest downstream application of the product.

MSD Animal Health, Boehringer Ingelheim, Zoetis, Ceva Santé Animale, and Elanco Animal Health are positioned among the leading global suppliers.

Market Trends
The product is evolving from conventional monovalent attenuated vaccines toward Multivalent/Combination Vaccines, recombinant live vectors, centralized hatchery immunization, and longer-duration protection. Conventional freeze-dried Newcastle Disease, Infectious Bronchitis, and Infectious Bursal Disease vaccines remain widely used through spray and drinking water for large-scale primary immunization, while HVT-vector technologies are increasing their share of higher-value programs by protecting against multiple diseases through vaccination of 18–19-day-old embryos or day-old chicks. Boehringer Ingelheim's VAXXITEK HVT+IBD+ND combines Marek's Disease, IBD, and ND protection on one live-vector platform, while Ceva's Vectormune ND uses HVT to express the NDV fusion protein. Future technology development will focus on maternal-antibody compatibility, reduced vaccine reactions, lower field-virus shedding, and automated hatchery administration.

Market Dynamics
Drivers
Demand for the product is mainly driven by scaling of commercial poultry production, routine infectious-disease prevention, and stronger biosecurity requirements in intensive farming systems. Newcastle Disease has worldwide relevance, and WOAH states that prophylactic vaccination is practiced in all but a few countries that produce poultry commercially, creating a stable base of vaccination demand. Broiler Farming has short production cycles and rapid flock turnover and therefore requires low-cost vaccination methods capable of treating large numbers of birds rapidly, giving spray and drinking-water live vaccines important operational advantages. Layer Farming and Breeder Farming require broader prime and booster programs, while centralized hatchery administration improves dose uniformity and reduces farm-level application variability.

Restraints
The main restraints are cold-chain requirements, consistency of field administration, maternal-antibody interference, and vaccine reactions associated with certain live strains. Freeze-dried vaccines commonly require refrigerated storage and rapid use after reconstitution, while disinfectants in drinking water, spray-droplet size, flock coverage, and environmental conditions can influence vaccination performance. MSD's ND Clone 30, for example, is stored at 2–8°C and may be administered through spray, drinking water, eye drop, or nasal drop. Certain respiratory modified-live vaccines may also cause temporary vaccination reactions, while frozen cell-associated Marek's Disease and HVT-vector products place greater demands on cold-chain management and hatchery capability, limiting convenience for smaller farms and lower-infrastructure markets.

Opportunities
Future opportunities are concentrated in Multivalent/Combination Vaccines, recombinant live vectors, automated hatchery vaccination, and more refined combinations of Prime and Booster Vaccines. Monovalent Vaccines provide flexibility for targeting individual diseases, but large integrated poultry producers increasingly seek to reduce handling and labor through one-dose protection against multiple diseases. VAXXITEK HVT+IBD+ND can be administered to 18–19-day-old embryos or day-old chicks across Broiler, Layer, and Breeder Farming and is offered in 2,000- and 4,000-dose presentations, illustrating the direction of multivalent hatchery vaccination. Conventional Newcastle and Infectious Bronchitis combinations also remain commercially important; Zoetis offers modified-live combination vaccines in 10,000-dose presentations for spray or drinking-water administration.

Challenges
The core challenge is maintaining sufficient immunogenicity while preserving attenuation stability and biological safety. Live organisms must retain enough replication capacity to stimulate immunity, but insufficient attenuation may increase reactions while excessive attenuation can weaken protection. Circulating strains, maternal-antibody levels, and production cycles vary substantially across regions, making a universal vaccination program impractical. Newcastle Disease and Infectious Bronchitis also involve strain and antigenic variation, requiring continuing validation of cross-protection. WOAH specifies seed-lot systems for live IB vaccines and emphasizes strict control of strain origin, purity, and freedom from extraneous agents, highlighting the importance of genetic stability and manufacturing consistency.

Industry Chain Analysis
The upstream supply chain mainly includes SPF embryonated eggs, avian cells and other culture substrates, master and working seed viruses, culture media, stabilizers, lyophilization protectants, sterile packaging, bioreactors, freeze dryers, filling equipment, and cold-chain systems. Midstream manufacturing includes seed expansion, egg- or cell-based propagation, harvesting of live viruses or bacteria, potency adjustment, formulation, freeze-drying or freezing, sterile filling, potency and purity testing, and batch release, with EID50, TCID50, and genetic stability serving as major quality parameters. WOAH describes live IB vaccines as commonly attenuated through repeated passages in SPF embryonated chicken eggs, while Newcastle live vaccine production can also use inoculated embryonated eggs for virus propagation. Downstream demand includes Broiler Farming, Layer Farming, Breeder Farming, and Other poultry operations and connects with hatcheries, veterinary distribution, spray systems, drinking-water vaccination equipment, in-ovo injectors, and cold-chain logistics.

Segment Insights
By disease type, Newcastle Disease Vaccines represent the core segment because vaccination is widely practiced across commercial poultry production. Traditional live strains include B1, LaSota, and Clone 30. MSD ND Clone 30 is a freeze-dried live vaccine containing ≥10^6 EID50 of Clone 30 per dose and can be used from one day of age. Infectious Bronchitis Vaccines frequently use Massachusetts, Connecticut, and other regional antigenic types and are often combined with ND, while IBD and Marek's Disease products are increasingly moving toward HVT-vector technologies.

By Antigen Combination, Monovalent Vaccines provide flexibility for targeting individual diseases or regional strains, while Multivalent/Combination Vaccines reduce the number of administrations. MSD Ma5+Clone 30 contains at least 10^3 EID50 of IB Ma5 and 10^6 EID50 of ND Clone 30 per dose. By Function, Prime Vaccines establish early immunity and are commonly administered in the hatchery or at day one, whereas Booster Vaccines maintain protection in long-cycle Layers and Breeders. The emerging technical route combines an HVT-vector Prime Vaccine with risk-based field boosters, shifting vaccination programs from repeated farm administration toward precise hatchery priming plus targeted boosting.

Downstream Market Opportunities
Broiler Farming represents the largest application because flocks are large, production cycles are short, and early protection against Newcastle Disease, Infectious Bronchitis, Infectious Bursal Disease, and Marek's Disease is critical, creating strong demand for day-one spray, drinking-water, and hatchery vector vaccination. Layer Farming has longer production cycles and therefore requires broader Prime and Booster programs, while Breeder Farming requires protection of breeding stock together with stable maternal-antibody transfer and generally uses more complex schedules. Boehringer Ingelheim's live-vector products are specifically positioned for broilers, commercial layers, and breeders. Artificial intelligence is not part of the vaccine itself, but it can combine mortality, antibody titers, production performance, environmental parameters, and regional outbreak data to optimize vaccination timing and booster intervals and can use machine vision and sensor systems to monitor hatchery spray uniformity.

Regional Insights
Asia-Pacific is an important production and consumption region because of its large Broiler, Layer, and Breeder industries and persistent demand for ND, IB, and IBD control. Chinese market participants include QYH Biotech, Pulike, Harbin Pharmaceutical Group, Jilin Zhengye, Shandong Huahong Biological Engineering, Yebio, Sinder, and DHN, while India includes Hester Biosciences, Globion India, and Venky's India; Nisseiken participates in Japan, KBNP in South Korea, and Vaksindo in Indonesia. North America has a highly integrated hatchery and poultry production system supporting mature automated vaccination, with MSD, Zoetis, Boehringer Ingelheim, and Elanco maintaining broad portfolios. Europe is advanced in HVT-vector technology, hatchery vaccination, and regulation, with Ceva, HIPRA, and Vaxxinova among relevant suppliers. WOAH notes that Newcastle Disease remains present in parts of Asia, Africa, and South America, maintaining long-term demand for cost-efficient live vaccines and reliable cold-chain supply.

Competitive Landscape Analysis
The product has substantial barriers in seed technology, biological manufacturing, biosafety, cold-chain management, and regulatory approval. Representative leading players include MSD Animal Health (Merck), Boehringer Ingelheim, Zoetis, Ceva Santé Animale, and Elanco Animal Health. MSD combines conventional Nobilis modified-live vaccines with Innovax HVT vectors across ND, IB, IBD, Marek's Disease, and combination programs; its official poultry portfolio includes dedicated ND, IB, ND+IB, IBD, and Marek's Disease categories. Boehringer Ingelheim has developed VAXXITEK into HVT+IBD and HVT+IBD+ND multivalent platforms; Zoetis uses Poulvac and established B1, LaSota, and Massachusetts live strains across respiratory and enteric disease programs; Ceva competes through the Vectormune HVT-vector platform for long-duration ND protection; and Elanco's AviPro portfolio covers live ND, IB, and Salmonella vaccines. Competition is shifting from basic potency toward multivalent protection, duration of immunity, hatchery automation, and complete vaccination-program services.

Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Live-type Poultry Vaccine market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.

Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.

Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation
By Company
MSD Animal Health（Merck）
Zoetis
Boehringer Ingelheim
Ceva Santé Animale
Elanco Animal Health
Phibro Animal Health
HIPRA
Vaxxinova
QYH Biotech
Pulike
Harbin Pharmaceutical Group
Nisseiken
Hester Biosciences
Globion India
Venkys India
KBNP
CAVAC
Bioveta
Vaksindo
Jilin Zhengye
Shandong Huahong Biological Engineering
Yebio
Sinder
DHN

Segment by Type
Newcastle Disease Vaccines
Infectious Bronchitis Vaccines
Infectious Bursal Disease Vaccines
Marek's Disease Vaccines
Others

Segment by Antigen Combination
Monovalent Vaccines
Multivalent / Combination Vaccines

Segment by Function
Preventive Vaccines
Prime Vaccines
Booster Vaccines

Segment by Application
Broiler Farming
Layer Farming
Breeder Farming
Others

Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA

Chapter Outline
Chapter 1: Defines the Live-type Poultry Vaccine study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.

Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).

Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.

Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).

Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).

Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Live-type Poultry Vaccine: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Live-type Poultry Vaccine Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Newcastle Disease Vaccines
1.2.3 Infectious Bronchitis Vaccines
1.2.4 Infectious Bursal Disease Vaccines
1.2.5 Marek's Disease Vaccines
1.2.6 Others
1.3 Market Segmentation by Antigen Combination
1.3.1 Global Live-type Poultry Vaccine Market Size by Antigen Combination, 2021 vs 2025 vs 2032
1.3.2 Monovalent Vaccines
1.3.3 Multivalent / Combination Vaccines
1.4 Market Segmentation by Function
1.4.1 Global Live-type Poultry Vaccine Market Size by Function, 2021 vs 2025 vs 2032
1.4.2 Preventive Vaccines
1.4.3 Prime Vaccines
1.4.4 Booster Vaccines
1.5 Market Segmentation by Application
1.5.1 Global Live-type Poultry Vaccine Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Broiler Farming
1.5.3 Layer Farming
1.5.4 Breeder Farming
1.5.5 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Live-type Poultry Vaccine Revenue Estimates and Forecasts (2021-2032)
2.2 Global Live-type Poultry Vaccine Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Live-type Poultry Vaccine Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Live-type Poultry Vaccine Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Newcastle Disease Vaccines: Market Share by Key Players
3.3.2 Infectious Bronchitis Vaccines: Market Share by Key Players
3.3.3 Infectious Bursal Disease Vaccines: Market Share by Key Players
3.3.4 Marek's Disease Vaccines: Market Share by Key Players
3.3.5 Others: Market Share by Key Players
3.4 Global Live-type Poultry Vaccine Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Live-type Poultry Vaccine Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Live-type Poultry Vaccine Market by Antigen Combination
4.2.1 Global Revenue by Antigen Combination (2021-2032)
4.2.2 Global Revenue-Based Market Share by Antigen Combination (2021-2032)
4.3 Global Live-type Poultry Vaccine Market by Function
4.3.1 Global Revenue by Function (2021-2032)
4.3.2 Global Revenue-Based Market Share by Function (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Live-type Poultry Vaccine Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Live-type Poultry Vaccine Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Live-type Poultry Vaccine Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Live-type Poultry Vaccine Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Live-type Poultry Vaccine Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Live-type Poultry Vaccine Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Live-type Poultry Vaccine Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Live-type Poultry Vaccine Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Live-type Poultry Vaccine Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Live-type Poultry Vaccine Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Live-type Poultry Vaccine Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 MSD Animal Health（Merck）
11.1.1 MSD Animal Health（Merck） Corporation Information
11.1.2 MSD Animal Health（Merck） Business Overview
11.1.3 MSD Animal Health（Merck） Live-type Poultry Vaccine Product Features and Attributes
11.1.4 MSD Animal Health（Merck） Live-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.1.5 MSD Animal Health（Merck） Live-type Poultry Vaccine Revenue by Product in 2025
11.1.6 MSD Animal Health（Merck） Live-type Poultry Vaccine Revenue by Application in 2025
11.1.7 MSD Animal Health（Merck） Live-type Poultry Vaccine Revenue by Geographic Area in 2025
11.1.8 MSD Animal Health（Merck） Live-type Poultry Vaccine SWOT Analysis
11.1.9 MSD Animal Health（Merck） Recent Developments
11.2 Zoetis
11.2.1 Zoetis Corporation Information
11.2.2 Zoetis Business Overview
11.2.3 Zoetis Live-type Poultry Vaccine Product Features and Attributes
11.2.4 Zoetis Live-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.2.5 Zoetis Live-type Poultry Vaccine Revenue by Product in 2025
11.2.6 Zoetis Live-type Poultry Vaccine Revenue by Application in 2025
11.2.7 Zoetis Live-type Poultry Vaccine Revenue by Geographic Area in 2025
11.2.8 Zoetis Live-type Poultry Vaccine SWOT Analysis
11.2.9 Zoetis Recent Developments
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Corporation Information
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Live-type Poultry Vaccine Product Features and Attributes
11.3.4 Boehringer Ingelheim Live-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.3.5 Boehringer Ingelheim Live-type Poultry Vaccine Revenue by Product in 2025
11.3.6 Boehringer Ingelheim Live-type Poultry Vaccine Revenue by Application in 2025
11.3.7 Boehringer Ingelheim Live-type Poultry Vaccine Revenue by Geographic Area in 2025
11.3.8 Boehringer Ingelheim Live-type Poultry Vaccine SWOT Analysis
11.3.9 Boehringer Ingelheim Recent Developments
11.4 Ceva Santé Animale
11.4.1 Ceva Santé Animale Corporation Information
11.4.2 Ceva Santé Animale Business Overview
11.4.3 Ceva Santé Animale Live-type Poultry Vaccine Product Features and Attributes
11.4.4 Ceva Santé Animale Live-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.4.5 Ceva Santé Animale Live-type Poultry Vaccine Revenue by Product in 2025
11.4.6 Ceva Santé Animale Live-type Poultry Vaccine Revenue by Application in 2025
11.4.7 Ceva Santé Animale Live-type Poultry Vaccine Revenue by Geographic Area in 2025
11.4.8 Ceva Santé Animale Live-type Poultry Vaccine SWOT Analysis
11.4.9 Ceva Santé Animale Recent Developments
11.5 Elanco Animal Health
11.5.1 Elanco Animal Health Corporation Information
11.5.2 Elanco Animal Health Business Overview
11.5.3 Elanco Animal Health Live-type Poultry Vaccine Product Features and Attributes
11.5.4 Elanco Animal Health Live-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.5.5 Elanco Animal Health Live-type Poultry Vaccine Revenue by Product in 2025
11.5.6 Elanco Animal Health Live-type Poultry Vaccine Revenue by Application in 2025
11.5.7 Elanco Animal Health Live-type Poultry Vaccine Revenue by Geographic Area in 2025
11.5.8 Elanco Animal Health Live-type Poultry Vaccine SWOT Analysis
11.5.9 Elanco Animal Health Recent Developments
11.6 Phibro Animal Health
11.6.1 Phibro Animal Health Corporation Information
11.6.2 Phibro Animal Health Business Overview
11.6.3 Phibro Animal Health Live-type Poultry Vaccine Product Features and Attributes
11.6.4 Phibro Animal Health Live-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.6.5 Phibro Animal Health Recent Developments
11.7 HIPRA
11.7.1 HIPRA Corporation Information
11.7.2 HIPRA Business Overview
11.7.3 HIPRA Live-type Poultry Vaccine Product Features and Attributes
11.7.4 HIPRA Live-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.7.5 HIPRA Recent Developments
11.8 Vaxxinova
11.8.1 Vaxxinova Corporation Information
11.8.2 Vaxxinova Business Overview
11.8.3 Vaxxinova Live-type Poultry Vaccine Product Features and Attributes
11.8.4 Vaxxinova Live-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.8.5 Vaxxinova Recent Developments
11.9 QYH Biotech
11.9.1 QYH Biotech Corporation Information
11.9.2 QYH Biotech Business Overview
11.9.3 QYH Biotech Live-type Poultry Vaccine Product Features and Attributes
11.9.4 QYH Biotech Live-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.9.5 QYH Biotech Recent Developments
11.10 Pulike
11.10.1 Pulike Corporation Information
11.10.2 Pulike Business Overview
11.10.3 Pulike Live-type Poultry Vaccine Product Features and Attributes
11.10.4 Pulike Live-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Harbin Pharmaceutical Group
11.11.1 Harbin Pharmaceutical Group Corporation Information
11.11.2 Harbin Pharmaceutical Group Business Overview
11.11.3 Harbin Pharmaceutical Group Live-type Poultry Vaccine Product Features and Attributes
11.11.4 Harbin Pharmaceutical Group Live-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.11.5 Harbin Pharmaceutical Group Recent Developments
11.12 Nisseiken
11.12.1 Nisseiken Corporation Information
11.12.2 Nisseiken Business Overview
11.12.3 Nisseiken Live-type Poultry Vaccine Product Features and Attributes
11.12.4 Nisseiken Live-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.12.5 Nisseiken Recent Developments
11.13 Hester Biosciences
11.13.1 Hester Biosciences Corporation Information
11.13.2 Hester Biosciences Business Overview
11.13.3 Hester Biosciences Live-type Poultry Vaccine Product Features and Attributes
11.13.4 Hester Biosciences Live-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.13.5 Hester Biosciences Recent Developments
11.14 Globion India
11.14.1 Globion India Corporation Information
11.14.2 Globion India Business Overview
11.14.3 Globion India Live-type Poultry Vaccine Product Features and Attributes
11.14.4 Globion India Live-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.14.5 Globion India Recent Developments
11.15 Venkys India
11.15.1 Venkys India Corporation Information
11.15.2 Venkys India Business Overview
11.15.3 Venkys India Live-type Poultry Vaccine Product Features and Attributes
11.15.4 Venkys India Live-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.15.5 Venkys India Recent Developments
11.16 KBNP
11.16.1 KBNP Corporation Information
11.16.2 KBNP Business Overview
11.16.3 KBNP Live-type Poultry Vaccine Product Features and Attributes
11.16.4 KBNP Live-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.16.5 KBNP Recent Developments
11.17 CAVAC
11.17.1 CAVAC Corporation Information
11.17.2 CAVAC Business Overview
11.17.3 CAVAC Live-type Poultry Vaccine Product Features and Attributes
11.17.4 CAVAC Live-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.17.5 CAVAC Recent Developments
11.18 Bioveta
11.18.1 Bioveta Corporation Information
11.18.2 Bioveta Business Overview
11.18.3 Bioveta Live-type Poultry Vaccine Product Features and Attributes
11.18.4 Bioveta Live-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.18.5 Bioveta Recent Developments
11.19 Vaksindo
11.19.1 Vaksindo Corporation Information
11.19.2 Vaksindo Business Overview
11.19.3 Vaksindo Live-type Poultry Vaccine Product Features and Attributes
11.19.4 Vaksindo Live-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.19.5 Vaksindo Recent Developments
11.20 Jilin Zhengye
11.20.1 Jilin Zhengye Corporation Information
11.20.2 Jilin Zhengye Business Overview
11.20.3 Jilin Zhengye Live-type Poultry Vaccine Product Features and Attributes
11.20.4 Jilin Zhengye Live-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.20.5 Jilin Zhengye Recent Developments
11.21 Shandong Huahong Biological Engineering
11.21.1 Shandong Huahong Biological Engineering Corporation Information
11.21.2 Shandong Huahong Biological Engineering Business Overview
11.21.3 Shandong Huahong Biological Engineering Live-type Poultry Vaccine Product Features and Attributes
11.21.4 Shandong Huahong Biological Engineering Live-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.21.5 Shandong Huahong Biological Engineering Recent Developments
11.22 Yebio
11.22.1 Yebio Corporation Information
11.22.2 Yebio Business Overview
11.22.3 Yebio Live-type Poultry Vaccine Product Features and Attributes
11.22.4 Yebio Live-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.22.5 Yebio Recent Developments
11.23 Sinder
11.23.1 Sinder Corporation Information
11.23.2 Sinder Business Overview
11.23.3 Sinder Live-type Poultry Vaccine Product Features and Attributes
11.23.4 Sinder Live-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.23.5 Sinder Recent Developments
11.24 DHN
11.24.1 DHN Corporation Information
11.24.2 DHN Business Overview
11.24.3 DHN Live-type Poultry Vaccine Product Features and Attributes
11.24.4 DHN Live-type Poultry Vaccine Revenue and Gross Margin (2021-2026)
11.24.5 DHN Recent Developments

12 Live-type Poultry Vaccine Value Chain and Ecosystem Analysis
12.1 Live-type Poultry Vaccine Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Live-type Poultry Vaccine Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Live-type Poultry Vaccine Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Live-type Poultry Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Live-type Poultry Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Live-type Poultry Vaccine Market Size Growth Rate by Function, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Live-type Poultry Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Live-type Poultry Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Live-type Poultry Vaccine Revenue by Region (US$ Million), 2021-2026
Table 7. Global Live-type Poultry Vaccine Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Live-type Poultry Vaccine Revenue by Players (US$ Million), 2021-2026
Table 10. Global Live-type Poultry Vaccine Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Live-type Poultry Vaccine Revenue, 2025
Table 13. Global Live-type Poultry Vaccine Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Live-type Poultry Vaccine Companies Headquarters
Table 15. Global Live-type Poultry Vaccine Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Live-type Poultry Vaccine Revenue by Type (US$ Million), 2021-2026
Table 19. Global Live-type Poultry Vaccine Revenue by Type (US$ Million), 2027-2032
Table 20. Global Live-type Poultry Vaccine Revenue by Antigen Combination (US$ Million), 2021-2026
Table 21. Global Live-type Poultry Vaccine Revenue by Antigen Combination (US$ Million), 2027-2032
Table 22. Global Live-type Poultry Vaccine Revenue by Function (US$ Million), 2021-2026
Table 23. Global Live-type Poultry Vaccine Revenue by Function (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Live-type Poultry Vaccine Revenue by Application (US$ Million), 2021-2026
Table 26. Global Live-type Poultry Vaccine Revenue by Application (US$ Million), 2027-2032
Table 27. Live-type Poultry Vaccine High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Live-type Poultry Vaccine Growth Accelerators and Market Barriers
Table 31. North America Live-type Poultry Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Live-type Poultry Vaccine Growth Accelerators and Market Barriers
Table 33. Europe Live-type Poultry Vaccine Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Live-type Poultry Vaccine Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Live-type Poultry Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Live-type Poultry Vaccine Investment Opportunities and Key Challenges
Table 37. Central and South America Live-type Poultry Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Live-type Poultry Vaccine Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Live-type Poultry Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. MSD Animal Health（Merck） Corporation Information
Table 41. MSD Animal Health（Merck） Description and Major Businesses
Table 42. MSD Animal Health（Merck） Product Features and Attributes
Table 43. MSD Animal Health（Merck） Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. MSD Animal Health（Merck） Revenue Proportion by Product in 2025
Table 45. MSD Animal Health（Merck） Revenue Proportion by Application in 2025
Table 46. MSD Animal Health（Merck） Revenue Proportion by Geographic Area in 2025
Table 47. MSD Animal Health（Merck） Live-type Poultry Vaccine SWOT Analysis
Table 48. MSD Animal Health（Merck） Recent Developments
Table 49. Zoetis Corporation Information
Table 50. Zoetis Description and Major Businesses
Table 51. Zoetis Product Features and Attributes
Table 52. Zoetis Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Zoetis Revenue Proportion by Product in 2025
Table 54. Zoetis Revenue Proportion by Application in 2025
Table 55. Zoetis Revenue Proportion by Geographic Area in 2025
Table 56. Zoetis Live-type Poultry Vaccine SWOT Analysis
Table 57. Zoetis Recent Developments
Table 58. Boehringer Ingelheim Corporation Information
Table 59. Boehringer Ingelheim Description and Major Businesses
Table 60. Boehringer Ingelheim Product Features and Attributes
Table 61. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Boehringer Ingelheim Revenue Proportion by Product in 2025
Table 63. Boehringer Ingelheim Revenue Proportion by Application in 2025
Table 64. Boehringer Ingelheim Revenue Proportion by Geographic Area in 2025
Table 65. Boehringer Ingelheim Live-type Poultry Vaccine SWOT Analysis
Table 66. Boehringer Ingelheim Recent Developments
Table 67. Ceva Santé Animale Corporation Information
Table 68. Ceva Santé Animale Description and Major Businesses
Table 69. Ceva Santé Animale Product Features and Attributes
Table 70. Ceva Santé Animale Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Ceva Santé Animale Revenue Proportion by Product in 2025
Table 72. Ceva Santé Animale Revenue Proportion by Application in 2025
Table 73. Ceva Santé Animale Revenue Proportion by Geographic Area in 2025
Table 74. Ceva Santé Animale Live-type Poultry Vaccine SWOT Analysis
Table 75. Ceva Santé Animale Recent Developments
Table 76. Elanco Animal Health Corporation Information
Table 77. Elanco Animal Health Description and Major Businesses
Table 78. Elanco Animal Health Product Features and Attributes
Table 79. Elanco Animal Health Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Elanco Animal Health Revenue Proportion by Product in 2025
Table 81. Elanco Animal Health Revenue Proportion by Application in 2025
Table 82. Elanco Animal Health Revenue Proportion by Geographic Area in 2025
Table 83. Elanco Animal Health Live-type Poultry Vaccine SWOT Analysis
Table 84. Elanco Animal Health Recent Developments
Table 85. Phibro Animal Health Corporation Information
Table 86. Phibro Animal Health Description and Major Businesses
Table 87. Phibro Animal Health Product Features and Attributes
Table 88. Phibro Animal Health Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Phibro Animal Health Recent Developments
Table 90. HIPRA Corporation Information
Table 91. HIPRA Description and Major Businesses
Table 92. HIPRA Product Features and Attributes
Table 93. HIPRA Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. HIPRA Recent Developments
Table 95. Vaxxinova Corporation Information
Table 96. Vaxxinova Description and Major Businesses
Table 97. Vaxxinova Product Features and Attributes
Table 98. Vaxxinova Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Vaxxinova Recent Developments
Table 100. QYH Biotech Corporation Information
Table 101. QYH Biotech Description and Major Businesses
Table 102. QYH Biotech Product Features and Attributes
Table 103. QYH Biotech Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. QYH Biotech Recent Developments
Table 105. Pulike Corporation Information
Table 106. Pulike Description and Major Businesses
Table 107. Pulike Product Features and Attributes
Table 108. Pulike Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. Pulike Recent Developments
Table 110. Harbin Pharmaceutical Group Corporation Information
Table 111. Harbin Pharmaceutical Group Description and Major Businesses
Table 112. Harbin Pharmaceutical Group Product Features and Attributes
Table 113. Harbin Pharmaceutical Group Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Harbin Pharmaceutical Group Recent Developments
Table 115. Nisseiken Corporation Information
Table 116. Nisseiken Description and Major Businesses
Table 117. Nisseiken Product Features and Attributes
Table 118. Nisseiken Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. Nisseiken Recent Developments
Table 120. Hester Biosciences Corporation Information
Table 121. Hester Biosciences Description and Major Businesses
Table 122. Hester Biosciences Product Features and Attributes
Table 123. Hester Biosciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Hester Biosciences Recent Developments
Table 125. Globion India Corporation Information
Table 126. Globion India Description and Major Businesses
Table 127. Globion India Product Features and Attributes
Table 128. Globion India Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. Globion India Recent Developments
Table 130. Venkys India Corporation Information
Table 131. Venkys India Description and Major Businesses
Table 132. Venkys India Product Features and Attributes
Table 133. Venkys India Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. Venkys India Recent Developments
Table 135. KBNP Corporation Information
Table 136. KBNP Description and Major Businesses
Table 137. KBNP Product Features and Attributes
Table 138. KBNP Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. KBNP Recent Developments
Table 140. CAVAC Corporation Information
Table 141. CAVAC Description and Major Businesses
Table 142. CAVAC Product Features and Attributes
Table 143. CAVAC Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. CAVAC Recent Developments
Table 145. Bioveta Corporation Information
Table 146. Bioveta Description and Major Businesses
Table 147. Bioveta Product Features and Attributes
Table 148. Bioveta Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Bioveta Recent Developments
Table 150. Vaksindo Corporation Information
Table 151. Vaksindo Description and Major Businesses
Table 152. Vaksindo Product Features and Attributes
Table 153. Vaksindo Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. Vaksindo Recent Developments
Table 155. Jilin Zhengye Corporation Information
Table 156. Jilin Zhengye Description and Major Businesses
Table 157. Jilin Zhengye Product Features and Attributes
Table 158. Jilin Zhengye Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. Jilin Zhengye Recent Developments
Table 160. Shandong Huahong Biological Engineering Corporation Information
Table 161. Shandong Huahong Biological Engineering Description and Major Businesses
Table 162. Shandong Huahong Biological Engineering Product Features and Attributes
Table 163. Shandong Huahong Biological Engineering Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. Shandong Huahong Biological Engineering Recent Developments
Table 165. Yebio Corporation Information
Table 166. Yebio Description and Major Businesses
Table 167. Yebio Product Features and Attributes
Table 168. Yebio Revenue (US$ Million) and Gross Margin (2021-2026)
Table 169. Yebio Recent Developments
Table 170. Sinder Corporation Information
Table 171. Sinder Description and Major Businesses
Table 172. Sinder Product Features and Attributes
Table 173. Sinder Revenue (US$ Million) and Gross Margin (2021-2026)
Table 174. Sinder Recent Developments
Table 175. DHN Corporation Information
Table 176. DHN Description and Major Businesses
Table 177. DHN Product Features and Attributes
Table 178. DHN Revenue (US$ Million) and Gross Margin (2021-2026)
Table 179. DHN Recent Developments
Table 180. Technologies, Platforms and Infrastructure
Table 181. Distributors List
Table 182. Market Trends and Market Evolution
Table 183. Market Drivers and Opportunities
Table 184. Market Challenges, Risks, and Restraints
Table 185. Research Programs/Design for This Report
Table 186. Key Data Information from Secondary Sources
Table 187. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Live-type Poultry Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Newcastle Disease Vaccines Product Picture
Figure 3. Infectious Bronchitis Vaccines Product Picture
Figure 4. Infectious Bursal Disease Vaccines Product Picture
Figure 5. Marek's Disease Vaccines Product Picture
Figure 6. Others Product Picture
Figure 7. Global Live-type Poultry Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million)
Figure 8. Monovalent Vaccines Product Picture
Figure 9. Multivalent / Combination Vaccines Product Picture
Figure 10. Global Live-type Poultry Vaccine Market Size Growth Rate by Function, 2021 vs 2025 vs 2032 (US$ Million)
Figure 11. Preventive Vaccines Product Picture
Figure 12. Prime Vaccines Product Picture
Figure 13. Booster Vaccines Product Picture
Figure 14. Global Live-type Poultry Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 15. Broiler Farming
Figure 16. Layer Farming
Figure 17. Breeder Farming
Figure 18. Others
Figure 19. Live-type Poultry Vaccine Report Years Considered
Figure 20. Global Live-type Poultry Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 21. Global Live-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 22. Global Live-type Poultry Vaccine Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 23. Global Live-type Poultry Vaccine Revenue-Based Market Share by Region (2021-2032)
Figure 24. Global Live-type Poultry Vaccine Revenue-Based Market Share Ranking (2025)
Figure 25. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 26. Newcastle Disease Vaccines Revenue-Based Market Share by Player in 2025
Figure 27. Infectious Bronchitis Vaccines Revenue-Based Market Share by Player in 2025
Figure 28. Infectious Bursal Disease Vaccines Revenue-Based Market Share by Player in 2025
Figure 29. Marek's Disease Vaccines Revenue-Based Market Share by Player in 2025
Figure 30. Others Revenue-Based Market Share by Player in 2025
Figure 31. Global Live-type Poultry Vaccine Revenue-Based Market Share by Type (2021-2032)
Figure 32. Global Live-type Poultry Vaccine Revenue-Based Market Share by Antigen Combination (2021-2032)
Figure 33. Global Live-type Poultry Vaccine Revenue-Based Market Share by Function (2021-2032)
Figure 34. Global Live-type Poultry Vaccine Revenue-Based Market Share by Application (2021-2032)
Figure 35. North America Live-type Poultry Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 36. North America Top 5 Players Live-type Poultry Vaccine Revenue (US$ Million) in 2025
Figure 37. North America Live-type Poultry Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 38. US Live-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 39. Canada Live-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 40. Mexico Live-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 41. Europe Live-type Poultry Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 42. Europe Top 5 Players Live-type Poultry Vaccine Revenue (US$ Million) in 2025
Figure 43. Europe Live-type Poultry Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 44. Germany Live-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 45. France Live-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 46. U.K. Live-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 47. Italy Live-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 48. Russia Live-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 49. Asia-Pacific Live-type Poultry Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 50. Asia-Pacific Top 8 Players Live-type Poultry Vaccine Revenue (US$ Million) in 2025
Figure 51. Asia-Pacific Live-type Poultry Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 52. Indonesia Live-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 53. Japan Live-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 54. South Korea Live-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 55. Australia Live-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 56. India Live-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 57. Indonesia Live-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 58. Vietnam Live-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 59. Malaysia Live-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 60. Philippines Live-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 61. Singapore Live-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 62. Central and South America Live-type Poultry Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 63. Central and South America Top 5 Players Live-type Poultry Vaccine Revenue (US$ Million) in 2025
Figure 64. Central and South America Live-type Poultry Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 65. Brazil Live-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 66. Argentina Live-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 67. Middle East and Africa Live-type Poultry Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 68. Middle East and Africa Top 5 Players Live-type Poultry Vaccine Revenue (US$ Million) in 2025
Figure 69. Middle East and Africa Live-type Poultry Vaccine Revenue (US$ Million) by Application (2021-2032)
Figure 70. GCC Countries Live-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 71. Israel Live-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 72. Egypt Live-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 73. South Africa Live-type Poultry Vaccine Revenue (US$ Million), 2021-2032
Figure 74. Live-type Poultry Vaccine Value Chain Mapping
Figure 75. Channels of Distribution (Direct Vs Distribution)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed